We have a new and exciting opportunity for a highly motivated and enthusiastic Postdoctoral Researcher to contribute to the research of the Radiopharmacy and Molecular Imaging Group, led by Dr Bart Cornelissen. The aim of the Group is the development of novel radiopharmaceuticals for oncology.
You will undertake research into DNA damage repair modulation following radionuclide therapy with 177Lu-PSMA in prostate cancer models. The project involves in vitro and in vivo studies using tumour-bearing animals and you will be responsible for managing your own research and administrative activities. The role will include coordination of experiments, assisting with the supervision of students and generation of high quality data suitable for publication and for submission in the context of grant proposals. You will also present results, including at national and international meetings.
You will have a PhD (or be near to completion) in pharmacy, molecular biology, chemistry or a related science, with a strong interest in cancer biology, molecular imaging and/or radionuclide therapy. Strong experimental skills and a demonstrated ability to design and carry out laboratory studies using a range of biomedical (radionuclide therapy) techniques are essential requirements of the role. A Home Office personal licence (PIL) would be advantageous.
This is a full-time post available for 1 year in the first instance.
All applicants must complete a short application form and upload a CV and supporting statement.
The closing date for applications is 12.00 noon on 6 September 2019. Interviews are scheduled for 16 September 2019.